Xu Daoliang, Wang Ben, Chen Lijie, Zhang Huawei, Wang Xiangyang, Chen Jiaoxiang
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
Laboratory of Orthopaedics of Zhejiang Province, China.
J Bone Oncol. 2020 Jul 17;24:100306. doi: 10.1016/j.jbo.2020.100306. eCollection 2020 Oct.
In recent years, studies on bone lymphoma and its histologic types have reached a mature stage. However, reports on the incidence and incidence-based mortality trends of bone lymphoma are scanty.
Patients with bone lymphoma in the U.S. were selected from Surveillance, Epidemiology, and End Results (SEER) database (1975-2016), and categorized based on age, sex, race, tumor location, SEER Historic Stage A and histologic type. Data on the incidence (1975-2016) and incidence-based mortality (1985-2016) were directly obtained from the SEER program. Annual percentage change (APC) and 95% confidence intervals (CIs) were calculated using the joinpoint regression analysis program.
Overall, 13,058 bone lymphoma cases diagnosed in resident patients of the U.S. were included in incidence analysis between 1975 and 2016 as follows: 6080 cases in 1975-1999, 3796 cases in 2000-2009, and 3182 cases in 2010-2016. Of these cases, 6888 died of bone lymphoma between 1985 and 2016. The overall incidence rates dramatically increased from 0.89 per 100,000 person-years in 1975 to 1.36 per 100,000 person-years in 2016. Incidence trend sharply increased from 1975 to 2009, and then stabilized between 2009 and 2016. Overall incidence-based mortality trends sharply increased from 1985 to 2016 without a joinpoint. Following the demographic and tumor characteristics, the trends of incidence and incidence-based mortality exhibited similar patterns.
Considering various characteristics (age, sex, race, tumor location, SEER Historic Stage A, and histologic type), we established that the incidence trend of bone lymphoma has sharply been increasing over the decades, however, in the recent years, the trend has stabilized. Besides, between 1985 and 2016, the incidence-based mortality had been sharply increasing without a turning point. These findings could give insights for clinicians to elaborately assess the epidemiology and risk factors of bone lymphoma.
近年来，关于骨淋巴瘤及其组织学类型的研究已达到成熟阶段。然而，关于骨淋巴瘤发病率及基于发病率的死亡率趋势的报告却很少。
从监测、流行病学和最终结果（SEER）数据库（1975 - 2016年）中选取美国的骨淋巴瘤患者，并根据年龄、性别、种族、肿瘤位置、SEER历史分期A和组织学类型进行分类。发病率（1975 - 2016年）和基于发病率的死亡率（1985 - 2016年）的数据直接从SEER项目中获取。使用Joinpoint回归分析程序计算年度百分比变化（APC）和95%置信区间（CIs）。
总体而言，1975年至2016年期间，美国住院患者中确诊的13058例骨淋巴瘤病例纳入发病率分析如下：1975 - 1999年有6080例，2000 - 2009年有3796例，2010 - 2016年有3182例。在这些病例中，1985年至2016年期间有6888例死于骨淋巴瘤。总体发病率从1975年的每10万人年0.89急剧增加到2016年的每10万人年1.36。发病率趋势从1975年到2009年急剧上升，然后在2009年至2016年期间稳定下来。总体基于发病率的死亡率趋势从1985年到2016年急剧上升且无连接点。根据人口统计学和肿瘤特征，发病率和基于发病率的死亡率趋势呈现相似模式。
考虑到各种特征（年龄、性别、种族、肿瘤位置、SEER历史分期A和组织学类型），我们确定骨淋巴瘤的发病率趋势在过去几十年中急剧上升，然而，近年来该趋势已稳定下来。此外，在1985年至2016年期间，基于发病率的死亡率一直在急剧上升且无转折点。这些发现可为临床医生精心评估骨淋巴瘤的流行病学和危险因素提供见解。
